Search

Displaying results 5801 - 5810 of 10000 in total
  1. Drug

    Tovinontrine

    go.drugbank.com/drugs/DB16193
    Investigational

    Tovinontrine is under investigation in clinical trial NCT04474314 (A Study of IMR-687 in Subjects With Sickle Cell Disease). … Tovinontrine is an orally administered, highly selective phosphodiesterase 9 (PDE9) small molecule inhibitor.

  2. Drug

    Zilebesiran

    go.drugbank.com/drugs/DB18929
    Investigational

    Zilebesiran is under investigation in clinical trial NCT06272487 (Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care

  3. Drug

    ANA975

    go.drugbank.com/drugs/DB06490
    Experimental

    ANA975 is a toll-like receptor 7 agonist that is developed for the treatment of hepatitis C.

    Synonyms: AN 975
  4. Drug

    Rolofylline

    go.drugbank.com/drugs/DB12670
    Investigational

    Rolofylline is under clinical development by pharmaceutical company NovaCardia for the treatment of congestive heart failure.

  5. Drug

    DLO6002

    go.drugbank.com/drugs/DB05179
    Experimental

    DLO6002 is developed by Summit Corporation and is in phase I of clinical trials for the treatment of Parkinson's disease.

  6. Drug

    AVAC

    go.drugbank.com/drugs/DB05441
    Experimental

    It has been tested in uses related to asthma and in treating eczema and atopic dermatitis.

  7. Drug

    HCV-086

    go.drugbank.com/drugs/DB05884
    Experimental

    HCV-086 is a small molecule antiviral designed to block an enzyme required for the replication of the hepatitis C virus.

  8. Drug

    Methadyl acetate

    go.drugbank.com/drugs/DB01433
    ExperimentalIllicit

    It is used mainly in the treatment of narcotic dependence.

  9. Drug

    Brasofensine

    go.drugbank.com/drugs/DB04857
    Experimental

    In November 2001, NeuroSearch confirmed that the drug's development was discontinued in favor of NS 2230. … Brasofensine is an orally administered dopamine reuptake inhibitor being developed for the treatment of Parkinson's Disease. Phase I/II trials for brasofensine have been completed in the U.K.

  10. Drug

    NCX 950

    go.drugbank.com/drugs/DB05849
    Experimental

    NCX 950, beta2-adrenoceptor agonists is widely used in the treatment of pulmonary diseases.